Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued
Source: SeekingAlpha
2026-04-23 15:59:30 ET
Investment Overview
In my last note on Alnylam Pharmaceuticals ( ALNY ) for Seeking Alpha published at the end of October last year, I assigned the RNA-interference specialist drug developer's stock a Hold rating....
Read the full article on Seeking Alpha
For further details see:
Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued
Alnylam Pharmaceuticals Inc.
NASDAQ: ALNY
ALNY Trading
4.83% G/L:
$303.94 Last:
529,633 Volume:
$297.22 Open:
ALNY Latest News
June 03, 2026 04:45:00 pm
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
ALNY Stock Data
$42,146,950,218
131,611,785
0.16%
379
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
